Innogen Deepens Metabolic Focus as Efsubaglutide Launch Drives First Revenue but Widens Loss

Guangzhou Innogen Pharmaceutical Group Co Ltd Class H ( (HK:2591) ) has issued an update.

Guangzhou Innogen reported its first year of revenue of RMB131.5 million in 2025 as it shifted toward commercial operations, driven by the rollout of its core diabetes drug Efsubaglutide Alfa, though heavy investment in research, clinical programs and marketing led to a widened annual loss of RMB341.4 million. The company’s balance sheet strengthened with higher current assets and net assets, reflecting capital support for its expanding pipeline and commercialization push despite rising expenses.

Efsubaglutide Alfa secured regulatory approval and commercial launch in China for type 2 diabetes and was added to the National Reimbursement Drug List from early 2026, as well as China’s primary care diabetes guidelines, enhancing its market access and academic profile. Innogen advanced Efsubaglutide Alfa’s lifecycle by pursuing new indications in obesity, overweight, adolescent weight management, MASH and even companion animal diabetes and obesity, while building overseas clinical programs, next-generation ultra-long-acting formulations and an AI-enabled drug discovery platform to reinforce its positioning in the global metabolic disease field.

The most recent analyst rating on (HK:2591) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Guangzhou Innogen Pharmaceutical Group Co Ltd Class H stock, see the HK:2591 Stock Forecast page.

More about Guangzhou Innogen Pharmaceutical Group Co Ltd Class H

Guangzhou Innogen Pharmaceutical Group Co., Ltd. is a China-based biopharmaceutical company focused on metabolic diseases, transitioning from a pure research and development model to a dual R&D and commercialisation strategy. Its core product is Efsubaglutide Alfa, a humanised long-acting GLP-1 receptor agonist targeting type 2 diabetes and weight management, with strategic plans for both domestic and overseas markets.

Average Trading Volume: 813,992

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$9.87B

For an in-depth examination of 2591 stock, go to TipRanks’ Overview page.